se of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers

Phase 1

• Conditions: Patients with a iodine refractory thyroid carcinoma, who received an 18F -FDG PET/CT scan in routine clinical practice.; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2021-000456-19-BE
• Lead Sponsor: niversity Hospital Ghent

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-29
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

-Patient is 18 years or older.
-Signed Informed Consent.
-Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory.
-Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan.
-Female patients should be either post-menopausal, surgically sterile, or using effective contraceptive methods (failure rate less than 1% per year when used consistently and correctly: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

-Patient has known other active malignancy.
-Patient is potentially pregnant (urinary hCG test can be performed in case of doubt) or breastfeeding.
-Patient is mentally or legally incapacitated.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified